Recent news on Targretin

SRI International Reacquires Rights to Tirapazamine, a Phase III ...  -  May 8, 2007
PipelineReview.com (press release),Marketed examples of these drugs include Targretin® (bexarotene) and Halfan® (halofantrine). Additionally, working with government and industry partners,

SRI International Reacquires Rights to Tirapazamine, a Phase III ...  -  May 7, 2007
PharmaLive.com (press release),Marketed examples of these drugs include Targretin(R) (bexarotene) and Halfan(R) (halofantrine). Additionally, working with government and industry partners

Eisai acquires US oncology expert Morphotek for $325 million  -  Mar 23, 2007
Pharma Times (subscription),They were Ontak (denileukin diftitox) and Targretin (bexarotene) capsules and gel for T cell lymphoma, and Panretin (alitretinoin) gel, used to treat the

Ligand Pharmaceuticals Announces Fourth Quarter Results  -  Mar 16, 2007
PharmaLive.com (press release),The sale included Ligand's four marketed oncology drugs ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, Targretin(R) (bexarotene) gel 1%

Ligand Pharmaceuticals Announces Fourth Quarter Results  -  Mar 15, 2007
Business Wire (press release),The sale included Ligand’s four marketed oncology drugs ONTAK® (denileukin diftitox), Targretin® (bexarotene) capsules, Targretin® (bexarotene) gel 1% and

Eisai buy cancer antibody specialists  -  Mar 23, 2007
LabTechnologist.com,...cancer-related products from Ligand Pharmaceuticals last October: Ontak (denileukin), Panretin (alitretinoin) gel and Targretin (bexarotene) capsules

Eisai Taking Over Morphotek; $325M For Antibody Foothold  -  Mar 22, 2007
BioWorld Online,The deal involved the marketed products Ontak (denileukin diftitox), for cutaneous T-cell lymphoma; Targretin (bexarotene) gel and capsules, also for CTCL;

Company Profile for TRACON Pharmaceuticals, Inc.  -  Feb 9, 2007
Business Wire (press release),The management team has led or contributed to the development of six approved biopharmaceuticals: Rituxan®, Zevalin®, Viracept®, Targretin®, Macugen® and

Company Profile for Tracon Pharmaceuticals, Inc.  -  Feb 9, 2007
PharmaLive.com (press release),The management team has led or contributed to the development of six approved biopharmaceuticals: Rituxan(R), Zevalin(R), Viracept(R), Targretin(R),

Genmab Announces Early Results Of Ongoing HuMax-CD4 Trials  -  Dec 11, 2006
Medical News Today (press release),The pivotal study includes patients with MF who are refractory to or intolerant of Targretin(R) and one other standard therapy, and will treat a total of 88

FDA Warns Ligand on Marketing Materials  Nov 1, 2006
...warning letter posted to its Web site today, the Food and Drug Administration states that a case study used to promote the drugs Ontak and Targretin "is false ... -MSN Money Eisai Announces Completion of Acquisition of Four Oncology-Related ...  Oct 25, 2006
...obtained exclusive global rights to ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, Targretin(R) (bexarotene) gel 1% and Panretin(R ... -PR Newswire (press release), Ligand Completes Sale of Oncology Product Lines  Oct 25, 2006
The sale includes Ligand’s four marketed oncology drugs: ONTAK® (denileukin diftitox), Targretin® (bexarotene) capsules, Targretin® (bexarotene) gel 1 ... -Business Wire (press release), Ligand Pharm Given FDA Warning Over 'Misleading' Material  Oct 27, 2006
...distributed. The two drugs, Ontak and Targretin, are now owned by Eisai Inc., the US subsidiary of Tokyo-based Eisai Co. (4523.TO). ... -Therapeutics Daily (subscription) (press release), Genmab Announces Early Results Of Ongoing HuMax-CD4 Trials  -  Dec 11, 2006
Medical News Today (press release),The pivotal study includes patients with MF who are refractory to or intolerant of Targretin(R) and one other standard therapy, and will treat a total of 88

Ligand Announces Financial Results for Second Quarter of Fiscal ...  Aug 9, 2006
Sales of Targretin capsules increased to $5.0 million (up 6%) and $10.0 million (up 15%), respectively, for the three and six months ended June 30, 2006 ... -PharmaLive.com



Ligand Announces Financial Results for First Quarter of Fiscal ...  May 15, 2006
...same period in 2005 reflects a 48% increase of AVINZA(R) net sales to $32.5 million and, as expected, strong oncology sales growth led by Targretin(R) capsules ... - Genetic Engineering News





Ligand Announces Preliminary Unaudited Financial Results for 2005  Mar 16, 2006
Sales of Targretin(R) capsules increased to $5.6 million for the three months ended December 31, 2005 compared to $3.6 million for the same 2004 period. ... - Genetic Engineering News



March of Dimes Applauds FDA Monitoring Program  09 Feb 2006
...tests. Other brands of isotretinoin include Amnesteem, Claravis and Sotret. Other retinoids include Targretin and Vesanoid. The ... - PR Newswire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional